Table 2.
Efficacy results
| Variable | Evaluable patients (n = 22) |
|---|---|
| Best response, n (%) | |
| Complete response | 1 (5) |
| Partial response | 5 (23) |
| Stable diseasea | 8 (36) |
| Progressive disease | 8 (36) |
| Objective response rate, % (95% CI) | 27 (11–50) |
| Clinical benefit rateb, % (95% CI) | 50 (28–72) |
| Time to progression, months (median (95% CI)) | 6.4 (3.6–12.6) |
| Time to death, months (median (95% CI)) | 18.4 (13.4–31.4) |
a
25 patients had stable disease at ≥24 weeks.
b
Complete response + partial response + stable disease at ≥24 weeks.
CI = Confidence interval.